Induction of G2/M arrest by berberine via activation of PI3K/Akt and p38 in human chondrosarcoma cell line

Oncology Research

Volumn 22, Issue 3, 2014, Pages 147-157

  Eo, Seong Hui ^a   Kim, Ju Hee ^a   Kim, Song Ja ^a  

^a Kongju National University   (South Korea)

Author keywords

Berberine; Cell cycle arrest; Chondrosarcoma; Proliferation

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTINEOPLASTIC AGENT; BERBERINE; CELL CYCLE PROTEIN; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN CDC25; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CDC25C PROTEIN, HUMAN; CDK1 PROTEIN, HUMAN; CHROMONE DERIVATIVE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; IMIDAZOLE DERIVATIVE; MORPHOLINE DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE; PYRIDINE DERIVATIVE; RETINOBLASTOMA PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHONDROSARCOMA CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MTT ASSAY; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHONDROSARCOMA; DRUG EFFECTS; GENETICS; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

BERBERINE; CDC25 PHOSPHATASES; CELL LINE, TUMOR; CELL PROLIFERATION; CHONDROSARCOMA; CHROMONES; CYCLIN B1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; ENZYME ACTIVATION; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; IMIDAZOLES; MORPHOLINES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84937030505     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504015X14298122915583     Document Type: Article

References (32)

1. Galoian, K. A.; Guettouche, T.; Issac, B.; Qureshi, A.; Temple, H. T. Regulation of onco and tumor suppressor MiRNAs by mTORC1 inhibitor PRP-1 in human chondrosarcoma. Tumour Biol. 35:2335-2341; 2013.
2. Sun, Y.; Guo, W.; Ren, T.; Liang, W.; Zhou, W.; Lu, Q.; Jiao, G.; Yan, T. Gli1 inhibition suppressed cell growth and cell cycle progression and induced apoptosis as well as autophagy depending on ERK1/2 activity in human chondrosarcoma cells. Cell Death Dis. 5:e979; 2014.
3. Wu, C. M.; Li, T. M.; Tan, T. W.; Fong, Y. C.; Tang, C. H. Berberine reduces the metastasis of chondrosarcoma by modulating the αvβ3 integrin and the PKCδ, c-Src, and AP-1 signaling pathways. Evidence Based. Complement. Alternat. Med. 2013:423164; 2013.
4. 2/M phases via p53-dependent pathway. Virus Res. 178:241-251; 2013.
5. Ruppenthal, S. L.; Noll, A.; Gotz, C.; Montenarh, M. Interference between p53 and cdc25C in cell cycle regulation. Int. J. Oncol. 31:345-352; 2007.
6. Harbour, J. W.; Dean, D. C. The Rb/E2F pathway: Expanding roles and emerging paradigms. Genes. Dev. 14:2393-2409; 2000.
7. Nevins, J. R. The Rb/E2F pathway and cancer. Hum. Mol. Genet. 10:699-703; 2001.
8. 1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA 92:8493-8497; 1995.
9. Kulkarni, S. K.; Dhir, A. Berberine: A plant alkaloid with therapeutic potential for central nervous system disorders. Phytother. Res. 24:317-324; 2010.
10. Brents, L. K.; Medina-Bolivar, F.; Seely, K. A.; Nair, A.; Bratton, S. M.; Nopo-Olazabal, L.; Patel, R. Y.; Liu, H.; Doerksen, R. J.; Prather, P. L.; Radominska-Pandya, A. Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors. Xenobiotica 42:139-156; 2012.
11. Amin, A. H.; Subbaiah, T. V.; Abbasi, K. M. Berberine sulfate: Antimicrobial activity, bioassay, and mode of action. Can. J. Microbiol. 15:1067-1076; 1969.
12. Bova, S.; Padrini, R.; Goldman, W. F.; Berman, D. M.; Cargnelli, G. On the mechanism of vasodilating action of berberine: Possible role of inositol lipid signaling system. J. Pharmacol. Exp. Ther. 261:318-323; 1992.
13. Akhter, M. H.; Sabir, M.; Bhide, N. K. Anti-inflammatory effect of berberine in rats injected locally with cholera toxin. Indian. J. Med. Res. 65:133-141; 1977.
14. Lee, Y. S.; Kim, W. S.; Kim, K. H.; Yoon, M. J.; Shen, Y.; Ye, J. M.; Lee, C. H.; Oh, W. K.; Kim, C. T.; Hohnen-Behrens, C.; Gosby, A.; Kraegen, E. W.; James, D. E.; Kim, J. B. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55:2256-2264; 2006.
15. Kong, W.; Wei, J.; Abidi, P.; Lin, M.; Inaba, S.; Wang, Y.; Wang, Z.; Si, S.; Pan, H.; Wang, S.; Wu, J.; Wang, Y.; Li, Z.; Liu, J.; Jiang, J. D. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med. 10:1344-1351; 2004.
16. Diogo, C. V.; Machado, N. G.; Barbosa, I. A.; Serafim, T. L.; Burgeiro, A.; Oliveira, P. J. Berberine as a promising safe anti-cancer agent - Is there a role for mitochondria? Curr. Drug Targets 12:850-859; 2011.
17. Giacinti, C.; Giordano, A. RB and cell cycle progression. Oncogene 25:5220-5227; 2006.
18. 2 arrest. Mol. Cell. Biol. 13:6640-6652; 1993.
19. Li, B.; Li, J.; Xu, W. W.; Guan, X. Y.; Qin, Y. R.; Zhang, L. Y.; Law, S.; Tsao, S. W.; Cheung, A. L. Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway. Oncotarget 30:11576-11587; 2014.
20. Zheng, F.; Tang, Q.; Wu, J.; Zhao, S.; Liang, Z.; Li, L.; Wu, W.; Hann, S. p38alpha MAPK-mediated induction and interaction of FOXO3a and p53 contribute to the inhibited-growth and induced-apoptosis of human lung adenocarcinoma cells by berberine. J. Exp. Clin. Res. 33:36; 2014.
21. 2/M transition by p53. Oncogene 20:1803-1815; 2001.
22. Roninson, I. B. Oncogenic functions of tumour suppressor p21 (Waf1/Cip1/Sdi1): Association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 179:1-14; 2002.
23. Adriaenssens, E.; Lemoine, J.; El Yazidi-Belkoura, I.; Hondermarck, H. Growth signaling in breast cancer cells: Outcomes and promises of proteomics. Biochem. Pharmacol. 64:797-803; 2002.
24. 2/M-phase of the cell cycle. Anticancer Res. 26:1097-1104; 2006.
25. Chi, C. W.; Chang, Y. F.; Chao, T. W.; Chiang, S. H.; P'eng, F. K.; Lui, W. Y.; Liu, T. Y. Flow cytometric analysis of the effect of berberine on the expression of glucocorticoid receptors in human hepatoma HepG2 cells. Life Sci. 54:2099-2107; 1994.
26. Wang, L.; Cao, H.; Lu, N.; Lui, L.; Wang, B.; Hu, T.; Israel, D. A.; Peek, R. M. Jr.; Polk, D. B.; Yan, F. Berberine inhibits proliferation and down-regulates epidermal growth factor receptor through activation of Cbl in colon tumor cells. PLoS One 8:e56666; 2013.
27. Wu, K., Yang, Q.; Mu, Y.; Zhou, L.; Liu, Y.; Zhou, Q.; He, B. Berberine inhibits the proliferation of colon cancer cells by inactivating Wnt/beta-catenin signaling. Int. J. Oncol. 41:292-298; 2012.
28. Park, K. S.; Kim, J. B.; Lee, S. J.; Bae, J. Berberine-induced growth inhibition of epithelial ovarian carcinoma cell lines. J. Obstet. Gynaecol. Res. 38:535-540; 2012.
29. Wen, C. J.; Wu, L. X.; Fu, L. J.; Zhang, Y. W.; Zhang, X.; Zhou, H. H. Genomic screening for targets regulated by berberine in breast cancer cells. Asian Pac. J. Cancer Prev. 14:6089-6094; 2013.
30. Cai, Y.; Xia, Q.; Luo, R.; Huang, P.; Sun, Y.; Shi, Y.; Jing, W. Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. J. Nat. Med. 68:53-62; 2014.
31. Ma, C.; Tang, K.; Liu, Q.; Zhu, R.; Cao, Z. Calmodulin as a potential target by which berberine induces cell cycle arrest in human hepatoma Bel7402 cells. Chem. Biol. Drug Des. 81:775-783; 2013.
32. Li, X. K.; Motwani, M.; Tong, W.; Bornmann, W.; Schwartz, G. K. Huanglian, A. Chinese herbal extract, inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells. Mol. Pharmacol. 58:1287-1293; 2000.